Clinical Trials in Tennessee

Showing 17541-17560 of 20,239 trials

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648

This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks

Chronic Kidney Disease

Genzyme, a Sanofi Company80 participantsStarted Mar 2005

Mobile, Alabama, United States • Riverside, California, United States • Greenwood Village, Colorado, United States +12 more locations

COMPLETEDPhase 229 miles

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00984542

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well bendamustine works as second- or third-line therapy in treating patients with relapsed or refractory small cell lung cancer.

Lung Cancer

Vanderbilt-Ingram Cancer Center50 participantsStarted Sep 2009

Elizabethtown, Kentucky, United States • Germantown, Tennessee, United States • Jackson, Tennessee, United States +3 more locations

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Find Trials by Condition in Tennessee

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

AMPED Outcomes Registry of Post-ED Pain Management

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Adult Double Cord Blood Transplant Study

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients